Cellmid Signs Antibody Humanisation Collaboration with Antitope

15-Apr-2011 - Australia

Cellmid Limited  has signed a collaboration agreement with Antitope Ltd for the humanisation of its lead therapeutic monoclonal antibody candidate. The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine antibody, using Cellmid’s patented sequence and Antitope’s proprietary EpiScreen™ and Composite Human Antibody™ technologies.

Antitope has already completed the interim milestone of producing a chimeric anti-midkine antibody, therefore significantly reducing the technical risks of the collaboration. The selection of the fully humanised lead is scheduled for Q3 2011.

As part of the agreement Antitope will also produce sufficient humanised antibody for preclinical testing using their proprietary high yielding CHO expression system.  Pre-clinical testing of the humanised drug candidate in several disease models is anticipated to commence in Q4 2011.

Midkine is a potent pro-inflammatory molecule contributing to disease in a number of inflammatory and autoimmune disorders and cancers. In preclinical studies Cellmid’s anti-midkine antibodies have reduced symptoms of inflammation by sequestering circulating midkine in the blood. It is anticipated that a humanised anti-midkine antibody will be a potent modulator of inflammation and autoimmunity and may contribute to the treatment of a number of diseases.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous